Cypris Therapeutics has introduced a breakthrough in synthetic chemistry technology which allows development of novel chemistries for treatment of therapeutically resistant diseases, including brain and pancreatic cancers.

"At Cypris Therapeutics, we are driven by a mission to develop life-saving therapies for some of the deadliest and therapeutically challenging diseases," said Kyle Parella, PhD, Co-Founder and CEO at Cypris.

"Our technology represents a new frontier in cancer treatment, offering hope to patients who currently have limited options," Parella added.

The company's proprietary technology enables the synthesis and iteration of complex small molecule moieties that have been previously unattainable by researchers. The molecules are inspired by those found in nature with demonstrated therapeutic properties. Cypris can modify these natural molecules to improve their therapeutic properties and reduce undesired side effects. This synthetic chemistry innovation holds the potential to significantly improve the standard of care for patients who do not respond to existing treatments.

Cypris Therapeutics has formed as the newest start-up in the portfolio of Ichor Life Sciences, a Syracuse-based contract research organization. Ichor is leading Cypris’s pre-seed funding round, which has already garnered over USD 500,000.

Cypris will incubate at Ichor's facilities and gain access to Ichor’s state-of-the-art equipment in addition to drug discovery and development expertise.

Ichor CEO and Founder Kelsey Moody, PhD, MBA stated, "We see vast potential in Cypris Therapeutics’ technology not only as a promising opportunity to develop next-generation oncology treatments, but as a platform for iterating natural products for other age-related indications where traditional medicinal chemistry approaches have been elusive.”

Cypris Therapeutics remains committed to its vision of delivering innovative cancer treatments that make a real difference in patients' lives. As the company moves forward, it continues to seek additional funding and partnerships to support its ambitious goals.